• Subscribe
  • Webinars
  • White Papers
  • Buyer's Guide
  • PhotonicsNXT
  • Get Published!
    • Recent Quotes
    My Watchlist
    Indicators
    BioOptics Stock Watch
    Markets
    Stocks
    ETFs
    Tools
    Overview
    News
    Currencies
    International
    Treasuries

    Vaneck Pharmaceutical ETF (NQ: PPH )

    92.16 +0.24 (+0.26%)
    Official Closing Price Updated: 4:15 PM EDT, Jun 21, 2024 Add to My Watchlist
    Quote
    Overview Detailed Quote Charting Historical Prices
    News
    All News News Headlines Press Releases
    Research
    Quarterly Reports Insider Filings Other Filings

    All News about Vaneck Pharmaceutical ETF

    Ozempic Maker Novo Nordisk Closes In On Lego As Denmark's Most Valuable Brand: Report
    Novo Nordisk is challenging Lego A/S for the title of Denmark's most valuable brand, with its brand value surging 59% to $5.1 billion. This growth is fueled by the global popularity of its weight-loss... 
    Via Benzinga
    Just Say No to Drugs: 3 Pharma Stocks to Avoid
    Discover which pharma stocks to avoid in 2023 as we delve into market trends, financial struggles, and the impact on investor portfolios. 
    Via InvestorPlace
    A Look At Pharma ETFs Post Q1 Earnings
    Pharma ETFs have delivered mixed performances over the past month. 
    Via Talk Markets
    Topics ETFs
    ETFs To Buy As Eli Lilly Beats Q1 Earnings, Lifts Outlook
    Eli Lilly and Company posted mixed first-quarter 2024 earnings, beating earnings estimates but lagging on revenues. Investors seeking to tap the opportune moment could bet on ETFs having the largest... 
    Via Talk Markets
    Topics ETFs
    3 Weight-Loss ETFs to Profit From the Obesity Drug Boom
    Leverage Oprah's shift to prescription weight solutions with Weight-Loss ETFs, targeting companies leading in obesity treatment. 
    Via InvestorPlace
    Topics ETFs
    Novo Nordisk's Game-Changer: FDA Approves Weight Loss Sensation Wegovy For Heart Health, Potential Insurance Coverage
    Novo Nordisk's Wegovy receives FDA approval for expanded use, targeting a significant reduction in cardiovascular events and weight management. 
    Via Benzinga
    Exposures Product Safety
    The Top 3 ETFs to Buy in March 2024
    Simplify your investment strategy through these top ETFs to buy, offering an excellent blend of diversification and upside. 
    Via InvestorPlace
    Topics ETFs
    11 'Granolas' Stocks Outperform Magnificent 7 With Lower Volatility, Higher Yields
    A group of stocks, which Goldman Sachs dubbed the "Granolas," accounted for 50% of gains of the Stoxx Europe 600 Index for the past year. 
    Via Benzinga
    A Look At Pharma ETFs After Q4 Earnings
    The fourth-quarter results of the healthcare sector have been unimpressive, with earnings of companies that have reported so far down 17.7% despite 7% revenue growth. 
    Via Talk Markets
    Topics ETFs
    5 ETF Zones Scaling New Highs At The Start Of 2024
    The start of 2024 has been weak for the global stock market after a blockbuster 2023. Still, a few corners of the stock market are outperforming, pushing ETFs to new 52-week highs. 
    Via Talk Markets
    Topics ETFs
    Government-granted Patent Monopolies Are Not The Free Market
    Our system for developing new drugs is a disaster. While we can point to great successes, they come at enormous cost. We will spend over $600B this year on prescription and non-prescription drugs -... 
    Via Talk Markets
    Topics Intellectual Property
    Exposures Intellectual Property
    Preparing For The Next Short-Term Rally Higher
    The short-term downtrend appears set to continue. The market is taking the time it needs to consolidate near its short-term trend lows in order to prepare a base from which it can begin its next... 
    Via Talk Markets
    Pharma ETFs in Focus Post Q2 Earnings
    Second-quarter earnings for the healthcare sector have been unimpressive, with earnings of companies that have reported so far down 30.7% on 5% revenue growth. 
    Via Talk Markets
    Topics ETFs
    The 3 Most Undervalued Pharma Stocks to Buy Now: July 2023
    Trading below a 15 forward price-to-earnings, these undervalued pharma stocks offer opportunities in an overbought market. 
    Via InvestorPlace
    Pharma ETFs Gain Post Q1 Earnings
    Pharma ETFs have been in the green over the past month. 
    Via Talk Markets
    A Look At Pharma ETFs Post Q4 Earnings
    Many industry bigwigs reported solid results, with some beating on earnings or revenues or both. However, solid earnings failed to fully impress pharma ETFs over the past month. 
    Via Talk Markets
    5 Sector ETFs That Beat The Market In December
    While most segments of the market are suffering from huge losses, a few have performed really well. These are likely to continue outperforming should the trends prevail. 
    Via Talk Markets
    Pharma ETFs In Focus Post Q3 Earnings
    Many industry bigwigs reported solid results with some beating on earnings or revenues or both. However, solid earnings failed to fully impress pharma ETFs over the past month. 
    Via Talk Markets
    Wave of Solid Q3 Earnings Push Pharma ETFs Higher
    The slew of Q3 results has led to smooth trading in pharma ETFs over the past month. 
    Via Talk Markets
    Pharma ETFs in Focus Post Q1 Earnings
    The slew of Q1 results has led to mixed trading in pharma ETFs over the past month. Here are those in detail. 
    Via Talk Markets
    Data & News supplied by www.cloudquote.io
    Stock quotes supplied by Barchart
    Quotes delayed at least 20 minutes.
    By accessing this page, you agree to the following
    Privacy Policy and Terms and Conditions.